Open Access
Subscription Access
Open Access
Subscription Access
Cholinesterase Inhibitor Induced Urinary Incontinence in Dementia:A Management Dilemma
Subscribe/Renew Journal
Cholinesterase inhibitors are effective pharmacological modality of treatment in patients with Alzheimer's disease. Urinary incontinence is a relatively uncommon side effect of cholinesterase inhibitors. It is difficult to differentiate the incontinence as a result of progression of the neurodegenerative process of dementia or due to medications or due to underlying local pathology (age-related). It seems illogical to recommend anticholinergics, which are commonly recommended for treatment of urinary incontinence, in patients with dementia who have already acetylcholine-deprived brain. We here discuss the management dilemma of urinary incontinence in a patient with Alzheimer's disease with review of literature.
Keywords
Cholinesterase Inhibitors, Dementia, Urinary Incontinence.
User
Subscription
Login to verify subscription
Font Size
Information
- Lanctot KL, Herrmann N, Yau KK, Khan LR, Liu BA, LouLou MM, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer’s disease: A meta-analysis. CMAJ. 2003; 169:557–64.
- Hashimoto M, Imamura T, Tanimukai S, Kazui H, Mori E. Urinary incontinence: An unrecognised adverse effect with donepezil. Lancet. 2000; 356:568.
- Kroger E, Van Marum R, Souverein P, Carmichael PH, Egberts T. Treatment with rivastigmine or galantamine and risk of urinary incontinence: Results from a Dutch database study. Pharmacoepidemiol Drug Saf. 2015; 24:276–85.
- Gill SS, Mamdani M, Naglie G, Streiner DL, Bronskill SE, Kopp A, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med. 2005; 165:808–13.
- DuBeau CE. Therapeutic/pharmacologic approaches to urinary incontinence in older adults. Clin Pharmacol Ther. 2009; 85:98–102.
- Sakakibara R, Uchiyama T, Yamanishi T, Kishi M. Dementia and lower urinary dysfunction: With a reference to anticholinergic use in elderly population. Int J Urol. 2008; 15:778–88.
- Siegler EL, Reidenberg M. Treatment of urinary incontinence with anticholinergics in patients taking cholinesterase inhibitors for dementia. Clin Pharmacol Ther. 2004; 75:484–8.
- Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol. 2001; 41:636–44.
- Fryer AD, Christopoulos A, Nathanson NM. Muscarinic Receptors: Springer Berlin Heidelberg. 2012; 391–99.
- Bezchlibnyk-Butler KZ, Jeffries JJ, Procyshyn RM, Virani AS. Clinical Handbook of Psychotropic Drugs. Goettingen, Germany: Hogrefe Publishing. 2013; 235–40.
- Sink KM, Thomas J III, Xu H, Craig B, Kritchevsky S, Sands LP. Dual use of bladder anticholinergics and cholinesterase inhibitors: Long-term functional and cognitive outcomes. J Am Geriatr Soc. 2008; 56:847–53.
Abstract Views: 569
PDF Views: 19